Searched for
MYLAN EXECUTIVE CHAIRMAN
Viatris president Rajiv Malik to retire in April next yearMalik was instrumental in the $12 billion merger of Mylan with Pfizer's generic drug unit that resulted in the creation of Viatris in 2019....- Glargine launch in US opens up a huge opportunity for Biocon: Kiran Mazumdar ShawEven as a biosimilar, it is estimated to be a $2.2-billion opportunity for Biocon and Mylan.
- Coronavirus: Niti CEO to find ways to reduce drug import dependence on ChinaThe list has been compiled by the drug regulatory authority and contains antibiotics like azithromycin, amoxicillin, ofloxacin, metronidazo...
- Temasek, TrueNorth-CPPIB seek to invest in Biocon BiologicsEye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.
- Culture of ‘bending rules’ in India challenges U.S. drug agencyThe US drug agency is bewildered with Indian pharma industry's culture of getting things done at all costs.
- Top stocks in focus on 10 October 2017Here is a list of top stocks that are likely to be in focus in today's trading session.
- Cipla reshuffles its senior management team againIndia’s third-largest drug maker Cipla has reshuffled its senior management team, the third time it’s doing so in as many years.
- Mylan fails in $26 bn bid to buy fellow drugmaker PerrigoMylan NV's $26 bn hostile bid for Perrigo collapsed on Friday after the Netherlands-based drugmaker failed to secure at least half of Perri...
- Mylan rejects Teva's $40 billion merger offer as undervaluedDrug major Mylan has rejected a $40 billion unsolicited merger offer from Israel's Teva Pharmaceutical Industries calling the bid undervalu...
- Teva’s hostile bid for Mylan: Deal could open up a $2-billion opportunity for pharma companiesAccording to experts, there is a possibility that the fruition of the deal will open up a $2-billion opportunity for Indian generic pharma ...
- Mylan Inc to acquire Famy Care's certain business for $ 800 millionMumbai-based Famy Care is focused on female reproductive health care and is world leader in supplying a wide range of contraceptive pills.
- Venus Pharma ties up with Mylan for marketing of antibiotic MeropenemThe deal with Mylan will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for a period of five years.
- Biocon posts 15% rise in revenue, names new CEOBiocon, the country's largest biotech company, reported a 15% rise in fourth-quarter revenue to 746 crore, helped by a 17% rise in sales at...
- Agila, with first class people, is a very high-quality asset: Rajiv MalikMylan has completed the acquisition of Agila Specialties division from Strides Arcolab for a total value of $1.75 billion (about Rs10,800 c...
- AIF Capital to invest $40 mn in Famy CareAIF Capital, one of the largest Asia-based independent private equity firms, on Wednesday announced that AIF Capital Asia III, LP has inves...
- Matrix weighs Docpharma saleHyderabad-based Matrix Labs, in which US-based Mylan Labs holds a controlling stake, is toning up its business focus.
- Mylan makes open offer for 20% stake in MatrixMP Laboratories (Mauritius) Ltd along with US-based generic pharma firm Mylan Laboratories Inc has issued an open offer to the shareholders...
- US pharma major Mylan buys Matrix LabsThe generic drugs major will acquir Hyderabad-based Matix Lab in a cash-and-stock deal worth Rs 3,424 cr.
- Mylan Labs to acquire 71.5% stake in MatrixIndian drug maker Matrix Laboratories Ltd on Monday said US-based generic pharma firm Mylan Laboratories Inc will acquire upto 71.5 per cen...
- Mylan to buy into MatrixMylan Laboratories’ India foray may be just round the corner - the US company is set to pick up a major stake in Secunderabad-based Matrix ...
Load More
